Page 70 - Revista Argentina de Transfusión 1 - 2020

21. Greco CA, Zhang JG, Kalab M, Yi QL, Ramirez-Arcos SM, 36. Reddoch-Cardenas KM, Montgomery RK, Lafleur CB, Peltier
Gyongyossy-Issa MIC. Effect of platelet additive solution on bac- GC, Bynum JA, Cap AP. Cold storage of platelets in platelet
terial dynamics and their influence on platelet quality in stored additive solution: an in vitro comparison of two Food and Drug
platelet concentrates. Transfusion. 2010;50(11):2344–52. Administration–approved collection and storage systems.
22. Yomtovian R, Jacobs MR. A prospective bonus of platelet stor- Transfusion. 2018 Jul 1;58(7):1682–8.
age additive solutions: A reduction in biofilm formation and 37. Wood B, Johnson L, Hyland RA, Marks DC. Maximising platelet
improved bacterial detection during platelet storage. Transfu- availability by delaying cold storage. Vox Sanguinis. 2018 Jul
sion. 2010 Nov;50(11):2295–300. 1;113(5):403–11.
23. Kreuger AL, Middelburg RA, Kerkhoffs JLH, Schipperus MR, 38. Scorer T, Williams A, Reddoch-Cardenas K, Mumford A. Manu-
Wiersum-Osselton JC, van der Bom JG. Storage medium of facturing variables and hemostatic function of cold-stored
platelet transfusions and the risk of transfusion-transmitted platelets: a systematic review of the literature. Vol. 59, Trans-
bacterial infections. Transfusion. 2017 Mar 1;57(3):657–60. fusion. Blackwell Publishing Inc.; 2019. p. 2722–32.
24. Galan AM, Lozano M, Molina P, Navalon F, Marschner S, Goodrich 39. Strandenes G, Kristoffersen E K, Bjerkvig C K FTK, Hervig T,
R, et al. Impact of pathogen reduction technology and storage Haaverstad R, Kvalheim V L ,Cap A P, Lunde T F, Braathen H,
in platelet additive solutions on platelet function. Transfusion. Sivertsen J AT. Cold-stored Apheresis Platelets in Treatment of
2011 Apr;51(4):808–15. Postoperative Bleeding in Cardiothoracic Surgery. In: Transfu-
25. Pagano MB, Katchatag BL, Khoobyari S, van Gerwen M, Sen N, sion. Wiley-Blackwell; 2016. p. (S4):S29–020B.
Rebecca Haley N, et al. Evaluating safety and cost-effectiveness 40. Kerkhoffs JLH, van Putten WLJ, Novotny VMJ, te Boekhorst
of platelets stored in additive solution (PAS-F) as a hemolysis PAW, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness
risk mitigation strategy. Transfusion. 2019 Apr 1;59(4):1246–51. of leucoreduced, pooled donor platelet concentrates, stored in
26. Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, plasma or additive solution with and without pathogen reduc-
Mounier C, et al. Comparison of the hemostatic efficacy of patho- tion. British Journal of Haematology. 2010 Jul;150(2):209–17.
gen-reduced platelets vs Untreated platelets in patients with throm- 41. Reddoch-Cardenas KM, Sharma U, Salgado CL, Montgomery
bocytopenia and malignant hematologic diseases: A randomized RK, Cantu C, Cingoz N, et al. An in vitro pilot study of apheresis
clinical trial. JAMA Oncology. 2018 Apr 1;4(4):468–75. platelets collected on Trima Accel system and stored in T-
27. Slichter SJ, Corson J, Jones MK, Christoffel T, Pellham E, Law- PAS+ solution at refrigeration temperature (1-6°C). Transfu-
rence Bailey S, et al. Exploratory studies of extended storage of sion. 2019 May 1;59(5):1789–98.
apheresis platelets in a platelet additive solution (PAS) Key 42. Braathen H, Sivertsen J, Lunde THF, Kristoffersen EK, Assmus
Points. 2014; Available from: www.bloodjournal.org J, Hervig TA, et al. In vitro quality and platelet function of cold
28. van der Meer PF, Pietersz RNI, Reesink HW. Storage of plate- and delayed cold storage of apheresis platelet concentrates in
lets in additive solution for up to 12 days with maintenance of platelet additive solution for 21 days. Transfusion.
good in-vitro quality. Vol. 44. 2004. 2019;59(8):2652–61.
29. Hornsey VS, McColl K, Drummond O, McMillan L, Morrison A, 43. Bynum JA, Taylor AS, Peltier GC, McIntosh CS, Meledeo MA,
Morrison L, et al. Extended storage of platelets in SSP+ plate- Dobson GP, et al. Evaluation of adenosine, lidocaine and mag-
let additive solution. Vox Sanguinis. 2006 Jul;91(1):41–6. nesium for enhancement of platelet function during storage.
30. Sweeney J, Kouttab N, Holme S, Kurtis J, Cheves T, Nelson E. Journal of Trauma and Acute Care Surgery. 2017 Apr 5;
Storage of platelet-rich plasma-derived platelet concentrate 44. McCullough J. Pathogen inactivation: A new paradigm for pre-
pools in plasma and additive solution. Transfusion. 2006 venting transfusion- transmitted infections. American Journal
May;46(5):835–40. of Clinical Pathology. 2007 Dec;128(6):945–55.
31. Ignatova AA, Karpova O v., Trakhtman PE, Rumiantsev SA, 45. Azuma H, Hirayama J, Akino M, Miura R, Kiyama Y, Imai K, et al.
Panteleev MA. Functional characteristics and clinical effec- Reduction in adverse reactions to platelets by the removal of
tiveness of platelet concentrates treated with riboflavin and plasma supernatant and resuspension in a new additive solu-
ultraviolet light in plasma and in platelet additive solution. Vox tion (M-sol). Transfusion. 2009 Feb;49(2):214–8.
Sanguinis. 2016 Apr 1;110(3):244–52. 46. van Rhenen DJ, Gullikssony H, Cazenavez JP, Pamphilon D,
32. Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis- Davis{ K, Flament J, et al. Therapeutic efficacy of pooled buffy-
derived platelets treated with riboflavin-ultraviolet light after coat platelet components prepared and stored with a platelet
resuspension in platelet additive solution. Transfusion. 2012 additive solution.
Mar;52(3):510–6. 47. Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M,
33. van der Meer PF, Bontekoe IJ, Daal BB, de Korte D. Riboflavin et al. Recovery and life span of 111indium-radiolabeled plate-
and UV light treatment of platelets: A protective effect of plate- lets treated with pathogen inactivation with amotosalen HCl
let additive solution? Transfusion. 2015 Aug 1;55(8):1900–8. (S-59) and ultraviolet a light. Transfusion. 2004 Dec;44(12):
34. Drawz SM, Marschner S, Yañez M, García De Coca A, Feys HB, 1732–40.
Deeren D, et al. Observational study of corrected count incre- 48. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A,
ments after transfusion of platelets treated with riboflavin Snyder E, et al. Therapeutic efficacy and safety of platelets
pathogen reduction technology in additive solutions. Transfu- treated with a photochemical process for pathogen inactiva-
sion. 2015 Jul 1;55(7):1745–51. tion: The SPRINT trial. Blood. 2004 Sep 1;104(5):1534–41.
35. Reddoch-Cardenas KM, Bynum JA, Meledeo MA, Nair PM, Wu 49. Janetzko K, Cazenave JP, Klüter H, Kientz D, Michel M, Beris P,
X, Darlington DN, et al. Cold-stored platelets: A product with et al. Therapeutic efficacy and safety of photochemically treated
function optimized for hemorrhage control. Vol. 58, Transfu- apheresis platelets processed with an optimized integrated
sion and Apheresis Science. Elsevier Ltd; 2019. p. 16–22. set. Transfusion. 2005;45(9):1443–52.

Pág. 64 AAHITC - Lavalleja 1214 (C1414DTZ) Vol. XLVI / N° 1 / 2020 Coordinadora: Dra. León de González, Graciela
Cdad. Aut. de Bs. As. - Argentina Págs. 57 / 65 Profesora invitada: Castilho, Lilian PhD
Tel/Fax: (54-11)4771-2501 - L.Rot.
E-mail: aahitc@aahitc.org.ar